Literature DB >> 15535413

The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients.

Julie M Yasuda1, Chris Miller, Judith S Currier, Donald N Forthal, Carol A Kemper, Gildon N Beall, Jeremiah G Tilles, Edmund V Capparelli, J Allen McCutchan, Richard H Haubrich.   

Abstract

BACKGROUND: Although adherence clearly influences response to antiretroviral therapy (ART), accurate assessment of adherence is problematic. The objective of this analysis was to assess the independent predictive value of protease inhibitor (PI) concentrations as a supplement to self-report as markers of medication adherence.
METHODS: This retrospective analysis was conducted from a prospective clinical trial designed to compare the outcomes of frequent versus infrequent HIV RNA measurement used to manage antiretroviral therapy. For 131 patients, self-reported medication adherence, HIV RNA levels, CD4 counts and PI concentrations (unannounced, random samples) were measured at baseline (when patients changed to a new regimen) and every 2 months thereafter. The change in HIV RNA from baseline to month 6 (area-based measure) was used to evaluate overall response. The proportion of measured PI concentrations below the detection limit was used as an alternative marker of adherence. An undetectable concentration would be expected after missing a single dose.
RESULTS: The mean baseline CD4 count was 125 cells/mm3 and the mean HIV RNA level was 4.7 log10 copies/ml. The mean change in log10 HIV RNA was -0.73 copies/ml. The mean percentage of self-reported adherence was 91% (range: 15-100%) and the mean proportion of undetectable PI concentrations was 27% (range: 0-100%, mean 2.5 samples/patient). The correlation between the two measures was -0.23 (P=0.009). In a multivariate model, percentage of visits with undetectable PI concentrations (P=0.02), percentage of medication adherence (P=0.02), baseline HIV RNA level (P=0.005), prior PI use (P=0.0004), prior lamivudine (3TC) use (P=0.0009) and randomization to the frequent HIV RNA measurement group (P<0.0001) were all related to change in HIV RNA. After accounting for adherence, patients who always had detectable PI concentrations had an average of 0.4 log10 additional HIV RNA reduction compared with those who had no detectable concentrations.
CONCLUSIONS: Repeated, random PI concentration values are independently predictive of virological response and may add to self-report of adherence in understanding the response to ART.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15535413

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  10 in total

Review 1.  Virologic response using directly observed therapy in adolescents with HIV: an adherence tool.

Authors:  Julia Bilodeau Purdy; Alexandra F Freeman; Staci C Martin; Celia Ryder; Deborah K Elliott-DeSorbo; Steven Zeichner; Rohan Hazra
Journal:  J Assoc Nurses AIDS Care       Date:  2008 Mar-Apr       Impact factor: 1.354

2.  Picomolar to Micromolar: Elucidating the Role of Distal Mutations in HIV-1 Protease in Conferring Drug Resistance.

Authors:  Mina Henes; Gordon J Lockbaum; Klajdi Kosovrasti; Florian Leidner; Gily S Nachum; Ellen A Nalivaika; Sook-Kyung Lee; Ean Spielvogel; Shuntai Zhou; Ronald Swanstrom; Daniel N A Bolon; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  ACS Chem Biol       Date:  2019-08-13       Impact factor: 5.100

Review 3.  Highly resistant HIV-1 proteases and strategies for their inhibition.

Authors:  Irene T Weber; Daniel W Kneller; Andres Wong-Sam
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

4.  Getting less of what you want: reductions in statistical power and increased bias when categorizing medication adherence data.

Authors:  Stephen J Tueller; Pascal R Deboeck; Richard A Van Dorn
Journal:  J Behav Med       Date:  2016-02-27

5.  Therapeutic Drug Monitoring of Lopinavir in HIV-Infected Children on Second-Line Antiretroviral Therapy in Asia.

Authors:  Linda Aurpibul; Sirinya Teerananchai; Wasana Prasitsuebsai; Tavitiya Sudjaritruk; Pope Kosalaraksa; Nia Kurniati; Khanh Huu Truong; Viet Chau Do; Lam Van Nguyen; Kulkanya Chokephaibulkit; Thida Singtoroj; Stephen J Kerr
Journal:  Ther Drug Monit       Date:  2016-12       Impact factor: 3.681

6.  Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel.

Authors:  Melanie A Thompson; Michael J Mugavero; K Rivet Amico; Victoria A Cargill; Larry W Chang; Robert Gross; Catherine Orrell; Frederick L Altice; David R Bangsberg; John G Bartlett; Curt G Beckwith; Nadia Dowshen; Christopher M Gordon; Tim Horn; Princy Kumar; James D Scott; Michael J Stirratt; Robert H Remien; Jane M Simoni; Jean B Nachega
Journal:  Ann Intern Med       Date:  2012-03-05       Impact factor: 25.391

7.  Mediating roles of medication-taking self-efficacy and depressive symptoms on self-reported medication adherence in persons with HIV: a questionnaire survey.

Authors:  Eunseok Cha; Judith A Erlen; Kevin H Kim; Susan M Sereika; Donna Caruthers
Journal:  Int J Nurs Stud       Date:  2007-10-22       Impact factor: 5.837

8.  HIV-1 Protease: Structural Perspectives on Drug Resistance.

Authors:  Irene T Weber; Johnson Agniswamy
Journal:  Viruses       Date:  2009-12-03       Impact factor: 5.048

9.  Correlation between lamivudine plasma concentrations and patient self-reported adherence to antiretroviral treatment in experienced HIV patients.

Authors:  Om Minzi; V Mugoyela; Ll Gustafsson
Journal:  Ther Clin Risk Manag       Date:  2011-11-22       Impact factor: 2.423

10.  Health care provider communication training in rural Tanzania empowers HIV-infected patients on antiretroviral therapy to discuss adherence problems.

Authors:  S Erb; E Letang; T R Glass; A Natamatungiro; D Mnzava; H Mapesi; M Haschke; U Duthaler; B Berger; L Muri; J Bader; C Marzolini; L Elzi; T Klimkait; W Langewitz; M Battegay
Journal:  HIV Med       Date:  2017-03-13       Impact factor: 3.180

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.